A Penn spin­out goes dark; Thumbs down on ALS drug; TIG­IT runs in­to PhI­II flop; Sanofi's got big plans; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Break­ing news and analy­sis are the bread and but­ter of End­points’ cov­er­age. But we can al­so go deep on cer­tain top­ics and fea­ture sto­ries, just like Nicole De­Feud­is did with psy­che­delics this week (ac­com­pa­nied by an ex­cel­lent we­bi­nar you can re­watch here). If you don’t al­ready, I en­cour­age you to check out our In Fo­cus chan­nel for the lat­est deep dives.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER